Q-omics provides the consensus-scored NME3 profile across patient tissues and cancer cell-line models. NME3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NME3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NME3 protein abundance shows 21,169 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where NME3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME3 survival associations across molecular data types. NME3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME3 RNA expression–survival associations across cancer types. High NME3 expression shows unfavorable associations in KIRC, SCLC, UVM, ACC, UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for NME3 RNA expression.
This table summarizes NME3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NME3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME3 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, LIHC, BRCA and CHOL. The KIRC box plot shows higher NME3 RNA expression in tumor versus normal tissue (log2 FC = +1.125, t-test p < 0.001).
This table shows molecular features associated with NME3 in patient tissues and cancer cell lines. In patient samples, NME3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NME3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
